The use of longitudinal18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Nedergaard, Mette K ^a   Kristoffersen, Karina ^b   Michaelsen, Signe R ^b   Madsen, Jacob ^a   Poulsen, Hans S ^b   Stockhausen, Marie Thérése ^b   Lassen, Ulrik ^b   Kjaer, Andreas ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; AMINO ACID TRANSPORTER LAT1; AMINO ACID TRANSPORTER LAT2; IRINOTECAN; KI 67 ANTIGEN; O (2 FLUOROETHYL) TYROSINE F 18; RADIOPHARMACEUTICAL AGENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG; (18F)FLUOROETHYLTYROSINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CANCER CELL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DRUG RESPONSE; DRUG UPTAKE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MICRO POSITRON EMISSION TOMOGRAPHY; MOUSE; NEUROIMAGING; NONHUMAN; NUDE MOUSE; ORTHOTOPIC TRANSPLANTATION; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; BRAIN NEOPLASMS; DIAGNOSTIC USE; DRUG EFFECTS; FEMALE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN; BRAIN NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; FEMALE; GLIOBLASTOMA; HETEROGRAFTS; HUMANS; MICE, NUDE; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; TYROSINE;

EID: 84903386154     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100009     Document Type: Article

References (35)

1. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, et al. (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28: 1963-1972.
2. Pope WB, Young JR, Ellingson BM (2011) Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep 11: 336-344.
3. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, et al. (2008) Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 49: 480-508. (Pubitemid 351355215)
4. Olivero WC, Dulebohn SC, Lister JR (1995) The use of PET in evaluating patients with primary brain tumours: is it useful? J Neurol Neurosurg Psychiatry 58: 250-252.
5. Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, et al. (2011) O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med 52: 856-864.
6. Galldiks N, Rapp M, Stoffels G, Fink GR, Shah NJ, et al. (2013) Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging 40: 22-33.
7. Galldiks N, Langen KJ, Holy R, Pinkawa M, Stoffels G, et al. (2012) Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. J Nucl Med 53: 1048-1057.
8. Heiss P, Mayer S, Herz M, Wester HJ, Schwaiger M, et al. (1999) Investigation of transport mechanism and uptake kinetics of O-(2-[18F] fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med 40: 1367-1373. (Pubitemid 29385647)
9. Langen KJ, Jarosch M, Muhlensiepen H, Hamacher K, Broer S, et al. (2003) Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol 30: 501-508. (Pubitemid 36776519)
10. Wiriyasermkul P, Nagamori S, Tominaga H, Oriuchi N, Kaira K, et al. (2012) Transport of 3-fluoro-L-alpha-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. J Nucl Med 53: 1253-1261.
11. Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, et al. (2006) O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33: 287-294.
12. Sai KK, Huang C, Yuan L, Zhou D, Piwnica-Worms D, et al. (2013) 18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas. J Nucl Med 54: 1120-1126.
13. Menichetti L, Petroni D, Panetta D, Burchielli S, Bortolussi S, et al. (2011) A micro-PET/CT approach using O-(2-[18F]fluoroethyl)-L-tyrosine in an experimental animal model of F98 glioma for BNCT. Appl Radiat Isot 69: 1717-1720.
14. Wang HE, Wu SY, Chang CW, Liu RS, Hwang LC, et al. (2005) Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model. Nucl Med Biol 32: 367-375.
15. Kim DK, Kim IJ, Hwang S, Kook JH, Lee MC, et al. (2004) System L-amino acid transporters are differently expressed in rat astrocyte and C6 glioma cells. Neurosci Res 50: 437-446. (Pubitemid 39572990)
16. Kristoffersen K, Villingshoj M, Poulsen HS, Stockhausen MT (2013) Level of Notch activation determines the effect on growth and stem cell-like features in glioblastoma multiforme neurosphere cultures. Cancer Biol Ther 14: 625-637. 24595.
17. Stockhausen MT, Broholm H, Villingshoj M, Kirchhoff M, Gerdes T, et al. (2011) Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme. Exp Cell Res 317: 1513-1526.
18. Verreault M, Strutt D, Masin D, Anantha M, Waterhouse D, et al. (2012) Irinophore C, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model. J Control Release 158: 34-43.
19. Kuroda J, Kuratsu J, Yasunaga M, Koga Y, Kenmotsu H, et al. (2010) Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab. Clin Cancer Res 16: 521-529.
20. El Ali HH, Bodholdt RP, Jørgensen JT, Myschetzky R, Kjaer A (2012) Importance of Attenuation Correction (AC) for Small Animal PET Imaging. Diagnostics 2: 42-51.
21. del Amo EM, Urtti A, Yliperttula M (2008) Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 35: 161-174.
22. Hellemans J, Mortier G, De PA, Speleman F, Vandesompele J (2007) qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 8: R19.
23. Gulyas B, Halldin C (2012) New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging 56: 173-190.
24. Nihashi T, Dahabreh IJ, Terasawa T (2013) PET in the clinical management of glioma: evidence map. AJR Am J Roentgenol 200: W654-W660.
25. Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, et al. (1999) Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 40: 205-212. (Pubitemid 29044193)
26. Fomchenko EI, Holland EC (2006) Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 12: 5288-5297. (Pubitemid 44497241)
27. Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K (2004) Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 31: 1464-1470. (Pubitemid 39592765)
28. Jeong SY, Lim SM (2012) Comparison of 3′-deoxy-3′-[18F] fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma. Nucl Med Biol 39: 977-981.
29. Wang L, Qu W, Lieberman BP, Plossl K, Kung HF (2011) Synthesis, uptake mechanism characterization and biological evaluation of (18)F labeled fluoroalkyl phenylalanine analogs as potential PET imaging agents. Nucl Med Biol 38: 53-62.
30. Haining Z, Kawai N, Miyake K, Okada M, Okubo S, et al. (2012) Relation of LAT1/4F2hc expression with pathological grade, proliferation and angiogenesis in human gliomas. BMC Clin Pathol 12: 4.
31. Lahoutte T, Caveliers V, Camargo SM, Franca R, Ramadan T, et al. (2004) SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation. J Nucl Med 45: 1591-1596. (Pubitemid 47618515)
32. Popperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, et al. (2007) FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 34: 1933-1942. (Pubitemid 350212135)
33. Vogel C, Marcotte EM (2012) Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 13: 227-232.
34. Galldiks N, Filss CP, Goldbrunner R, Langen KJ (2012) Discrepant MR and [(18)F]Fluoroethyl-L-Tyrosine PET Imaging Findings in a Patient with Bevacizumab Failure. Case Rep Oncol 5: 490-494.
35. Heinzel A, Muller D, Langen KJ, Blaum M, Verburg FA, et al. (2013) The Use of O-(2-18F-Fluoroethyl)-L-Tyrosine PET for Treatment Management of Bevacizumab and Irinotecan in Patients with Recurrent High-Grade Glioma: A Cost-Effectiveness Analysis. J Nucl Med 54: 1217-1222.